Since the launch of Nexium 24HR in May of 2014, the brand has generated approximately $300 million, “making it one of the largest and most successful Rx-to-OTC switches,” Ian Read, Pfizer chairman and CEO, recently told analysts.
The big story in the digestives space continues to be the switch and launch of Pfizer’s Nexium 24HR. For the 52 weeks ended June 14, sales of Nexium 24HR across total U.S. multi-outlets reached $278.7 million and are still climbing, according to IRI.
Tylenol has retaken the OTC pain relief aisle with a vengeance. The brand is close to reclaiming the top spot among internal analgesic tablets behind Aleve and Advil and is growing at a 10% rate on a dollar base of more than $250 million.
The top four best-selling internal analgesic brands — Advil, Aleve, Tylenol and Bayer — generate more than 40% of the overall $3.3 billion in internal analgesic tablet sales, according to IRI figures. But it’s the smaller niche external analgesic brands that are contributing a lot of incremental sales to the pain relief category.
While the first retail clinics began to enter chronic disease management going back as early as 2010, these efforts have been ramped up considerably in recent years as payers look more aggressively to lower costs and health systems look to drive improved patient outcomes.
“Average telehealth costs are $40 to $50 compared to $136 to $176 for a related in-person visit, while the most common diagnoses made during telehealth visits are sinusitis, cold, flu, pertussis and urinary tract infections,” according to the Robert Wood Johnson Foundation April 2015 report, “Building a culture of health: The value proposition.”
According to research conducted by Rand Corp., retail clinic traffic doubled each year between 2007 and 2009, to 6 million patient visits a year. Since then, the number has risen to more than 10.5 million in 2014 and rising, according to various estimates.
With the expansion of coverage to millions of more Americans in the years since the Affordable Care Act was fully implemented, access to care is becoming more strained than ever before, seemingly creating more interest among payers, insurers, health systems and patients in the use of retail clinics.